KalVista Pharma CMO Audhya sells $83k in shares
#KalVista Pharma #Paul Audhya #Insider Trading #EKTERLY #NASDAQ:KALV #Stock Sale #Hereditary Angioedema #Analyst Ratings
📌 Key Takeaways
- KalVista Pharma CMO Paul K. Audhya sold 5,354 shares worth approximately $83,344
- Audhya exercised options to acquire 11,250 shares in the preceding days
- KalVista's EKTERLY treatment exceeded Q4 revenue expectations with $35 million in sales
- Analysts have raised price targets for the company stock
📖 Full Retelling
KalVista Pharmaceuticals Inc (NASDAQ:KALV) Chief Medical Officer Paul K. Audhya sold 5,354 shares of common stock on February 23, 2026, according to a recent SEC filing, with the shares sold at a weighted average price of $15.5668 for a total transaction value of approximately $83,344. The prices for the sale ranged from $15.518 to $15.566982. The filing also indicates that on February 21 and 22, Audhya exercised options to acquire a total of 11,250 shares of KalVista Pharmaceuticals' common stock, involving the conversion of 11,250 restricted stock units into common stock. Following these transactions, Audhya directly owns 138,983 shares of KalVista Pharmaceuticals. The insider sale comes as the stock trades at $15.77, up 46% over the past year, with analysts setting price targets ranging from $22 to $39, suggesting the company appears undervalued at current levels. These transactions occurred amid positive developments for KalVista, as the company reported strong preliminary fourth-quarter revenue results for its oral hereditary angioedema treatment, EKTERLY, with global sales reaching approximately $35 million, significantly exceeding analysts' expectations of around $20 million. The full-year 2025 revenue for EKTERLY was approximately $49 million, highlighting the medication's robust market adoption since its launch in July 2025. The positive market reception is further supported by the International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema, which has recommended EKTERLY as a first-line therapy for acute treatment in adolescents aged 12 and older, prompting several analyst firms to adjust their outlooks, with Stifel reiterating its Buy rating with a $39.00 price target, Needham raising its price target to $35.00 from $32.00, and Citizens increasing its price target to $29.00 from $28.00, all citing the strong launch performance of EKTERLY.
🏷️ Themes
Insider Trading, Pharmaceutical Industry, Stock Market Performance
📚 Related People & Topics
Insider trading
Trading using nonpublic information
# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Entity Intersection Graph
Connections for Insider trading:
🌐
SEC filing
5 shared
👤
New York Stock Exchange
4 shared
👤
Rachel Haurwitz
3 shared
🌐
ZWS
2 shared
🌐
Biopharmaceutical
2 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Bitcoin slips, wipes out 50% from October record high at session low AMD stock surges 14% on Meta AI partnership deal Wall Street ends higher on tech rebound ahead of State of the Union address Software stocks rebound as Anthropic partnerships ease AI disruption fears (South Africa Philippines Nigeria) KalVista Pharma CMO Audhya sells $83k in shares By Investing.com Insider Trading Published 02/24/2026, 07:55 PM KalVista Pharma CMO Audhya sells $83k in shares 0 KALV 1.35% KalVista Pharmaceuticals Inc (NASDAQ:KALV) Chief Medical Officer Paul K. Audhya sold 5,354 shares of common stock on February 23, 2026, according to a recent SEC filing. The shares were sold at a weighted average price of $15.5668, for a total transaction value of approximately $83,344. The prices for the sale ranged from $15.518 to $15.566982. The filing also indicates that on February 21 and 22, Audhya exercised options to acquire a total of 11,250 shares of KalVista Pharmaceuticals’ common stock. These transactions involved the conversion of 11,250 restricted stock units into common stock. Following these transactions, Audhya directly owns 138,983 shares of KalVista Pharmaceuticals.The insider sale comes as the stock trades at $15.77, up 46% over the past year. According to InvestingPro analysis, the company appears undervalued at current levels, with analysts setting price targets ranging from $22 to $39. For deeper insights, investors can access comprehensive Pro Research Reports covering KALV and 1,400+ other US equities. In other recent news, KalVista Pharmaceuticals has reported strong preliminary fourth-quarter revenue results for its oral hereditary angioedema treatment, EKTERLY, with global sales reaching approximately $35 million. This figure significantly exceeded analysts’ expectations, which were around $20 million. The full-year 2025 revenue for EKTERLY was approximately $49 million, highlighting the medication’s robust marke...
Read full article at source